TNDM has 36-month beta value of 1.59. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 11 as “hold,” and 0 as “sell.”
The public float for TNDM is 65.75M, and currently, short sellers hold a 10.46% ratio of that float. The average trading volume of TNDM on May 15, 2025 was 1.90M shares.
TNDM) stock’s latest price update
The stock of Tandem Diabetes Care Inc (NASDAQ: TNDM) has decreased by -1.21 when compared to last closing price of 23.13. Despite this, the company has experienced a 2.65% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-02 that Tandem Diabetes’ Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
TNDM’s Market Performance
Tandem Diabetes Care Inc (TNDM) has experienced a 2.65% rise in stock performance for the past week, with a 34.17% rise in the past month, and a -30.57% drop in the past quarter. The volatility ratio for the week is 3.41%, and the volatility levels for the past 30 days are at 5.43% for TNDM. The simple moving average for the past 20 days is 16.66% for TNDM’s stock, with a -28.61% simple moving average for the past 200 days.
Analysts’ Opinion of TNDM
Many brokerage firms have already submitted their reports for TNDM stocks, with Mizuho repeating the rating for TNDM by listing it as a “Neutral.” The predicted price for TNDM in the upcoming period, according to Mizuho is $20 based on the research report published on April 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see TNDM reach a price target of $22, previously predicting the price at $45. The rating they have provided for TNDM stocks is “Equal-Weight” according to the report published on March 05th, 2025.
Citigroup gave a rating of “Neutral” to TNDM, setting the target price at $24 in the report published on March 04th of the current year.
TNDM Trading at 20.06% from the 50-Day Moving Average
After a stumble in the market that brought TNDM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.44% of loss for the given period.
Volatility was left at 5.43%, however, over the last 30 days, the volatility rate increased by 3.41%, as shares surge +29.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.24% upper at present.
During the last 5 trading sessions, TNDM rose by +2.65%, which changed the moving average for the period of 200-days by -42.95% in comparison to the 20-day moving average, which settled at $19.59. In addition, Tandem Diabetes Care Inc saw -36.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNDM starting from Kyrillos Jean-Claude, who purchase 10,538 shares at the price of $18.12 back on Mar 07 ’25. After this action, Kyrillos Jean-Claude now owns 10,538 shares of Tandem Diabetes Care Inc, valued at $190,966 using the latest closing price.
BLICKENSTAFF KIM D, the Director of Tandem Diabetes Care Inc, sale 30,000 shares at $31.38 during a trade that took place back on Nov 21 ’24, which means that BLICKENSTAFF KIM D is holding 165,190 shares at $941,400 based on the most recent closing price.
Stock Fundamentals for TNDM
Current profitability levels for the company are sitting at:
- -0.16 for the present operating margin
- 0.47 for the gross margin
The net margin for Tandem Diabetes Care Inc stands at -0.17. The total capital return value is set at -0.28. Equity return is now at value -92.31, with -19.74 for asset returns.
Based on Tandem Diabetes Care Inc (TNDM), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.03. The debt to equity ratio resting at 3.18. The interest coverage ratio of the stock is -32.32.
Currently, EBITDA for the company is -99.13 million with net debt to EBITDA at -2.92. When we switch over and look at the enterprise to sales, we see a ratio of 1.78. The receivables turnover for the company is 8.71for trailing twelve months and the total asset turnover is 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
To put it simply, Tandem Diabetes Care Inc (TNDM) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
